论文部分内容阅读
目的 :探讨血清中血管内皮生长因子(VEGF)及其亚型VEGF-A的水平与2型糖尿病肾病之间的关系,探讨依那普利对肾脏的保护作用是否与VEGF、VEGF-A血清水平相关。方法 :选取104例2型糖尿病患者,按照尿白蛋白水平分为A正常白蛋白尿组(35例)、B微量白蛋白尿组(40例)、C大量白蛋白尿组(29例),另选健康人作为D健康对照组(30例),检测各组血清VEGF及VEGF-A水平;将B组随机分为两组各20例,B1组口服依那普利作为治疗组,B2组行常规治疗作为对照组,检测治疗3个月后两组VEGF及VEGF-A的水平。结果 :2型糖尿病肾病各组患者中血清VEGF,特别是VEGF-A水平均较健康对照组明显升高,且C组>B组>A组;相关性分析:VEGF和VEGF-A与尿微量白蛋白、血肌酐呈正相关,与估算的肾小球滤过率呈负相关;依那普利治疗后患者血清VEGF和VEGF-A较治疗前明显下降。结论 :血清VEGF、VEGF-A可及时反映2型糖尿病肾病疾病进展,其中VEGF-A的敏感性及特异性更高,推测VGEF-A可作为早期诊断及监测2型糖尿病肾病疗效的最重要指标之一。
OBJECTIVE: To investigate the relationship between serum VEGF and its subtype of VEGF-A and type 2 diabetic nephropathy, and to investigate whether enalaprol’s renal protective effect is related to the serum levels of VEGF and VEGF-A Related. Methods: A total of 104 patients with type 2 diabetes mellitus (T2DM) were enrolled in this study. According to the level of urinary albumin, they were divided into A normal albuminuria group (35 cases), B microalbuminuria group (40 cases), C massive albuminuria group (29 cases) The other healthy individuals were selected as D healthy control group (30 cases). The levels of serum VEGF and VEGF-A in each group were detected. Group B was randomly divided into two groups of 20 cases. Group B1 was treated with enalapril as treatment group, group B2 Routine treatment as a control group, detection of three months after treatment, the two groups of VEGF and VEGF-A levels. Results: The levels of serum VEGF, especially VEGF-A in patients with type 2 diabetic nephropathy were significantly higher than those in healthy controls, and those in group C> B> A; Correlation analysis: The correlation between VEGF and VEGF- Albumin, serum creatinine was positively correlated with the estimated glomerular filtration rate was negatively correlated; enalapril treatment of patients with serum VEGF and VEGF-A than before treatment decreased significantly. Conclusion: Serum VEGF and VEGF-A can reflect the disease progression of type 2 diabetic nephropathy in a timely manner. The sensitivity and specificity of VEGF-A are higher. It is speculated that VGEF-A can be used as the most important indicator of early diagnosis and monitoring of type 2 diabetic nephropathy one.